Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
IPO Year: 2021
Exchange: NASDAQ
Website: sightsciences.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/21/2024 | $10.00 | Buy | Lake Street |
9/12/2023 | $10.00 → $4.50 | Neutral → Underperform | BofA Securities |
9/12/2023 | $15.00 → $5.50 | Overweight → Neutral | Piper Sandler |
9/12/2023 | Outperform → Mkt Perform | William Blair | |
8/24/2023 | $12.00 → $8.40 | Overweight → Equal-Weight | Morgan Stanley |
7/10/2023 | $15.00 → $9.00 | Buy → Neutral | Citigroup |
1/6/2023 | $10.00 → $15.00 | Hold → Buy | Stifel |
10/4/2022 | Hold | Needham | |
7/26/2022 | $10.00 | Hold | Stifel |
2/3/2022 | Outperform | William Blair |
MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference, in New York, NY. Sight Sciences' management is scheduled to present on Wednesday, September 4, 2024, at 1:50 pm PT / 4:50 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the company's website at: investors.sightsciences.com. About Sight SciencesSight Scienc
MENLO PARK, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the second quarter ended June 30, 2024, and narrowed financial guidance for full year 2024. Recent Business and Second Quarter 2024 Financial Highlights Generated total revenue of $21.4 million, an increase of 11% compared to the prior quarter and a decrease of 9% compared to the same period in the prior year.Achieved total gross margin of 86%
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 1, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.
MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its first Sustainability Report, highlighting the Company's sustainability activities, performance, and results from the last three years. "We are proud to issue our first annual Sustainability Report, showing our commitment to corporate sustainability initiatives and enhanced disclosures," stated Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences. He continued,
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops ("Restasis") had additional clinically meaningful improvements in the signs and symptoms of dry eye disease ("DED") when crossed over to TearCare. These improvements persisted for six months through month twelve wi
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) study data. This new analysis evaluated the association between the severity of glaucoma and the intraocular pressure ("IOP") and medication outcomes for patients treated with the OMNI Surgical System ("OMNI"). OMNI enables a proced
MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will present at the upcoming Bank of America Healthcare Conference, in Las Vegas, NV. Sight Sciences' management is scheduled to present on Tuesday, May 14, 2024, at 8:15 am PT / 11:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the company's website at: investors.sightsciences.com. About Sight Sciences Sight Sciences is an eyecare
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the first quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. Recent Business and Financial Highlights Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.Achieved total gross margin of 86% in the first quarter of 2024 compared to 84% in the same period in the prior year.Reduced ca
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a positive jury trial verdict of $34 million associated with the patent infringement case it filed on September 16, 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, "Alcon") in the U.S. District Court for the District of Delaware. Sight Sciences asserted that Alcon's and Ivantis' sale of the Hydrus® Microstent infringed three key patents. The verdict was a
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.co
Lake Street initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $10.00
BofA Securities downgraded Sight Sciences from Neutral to Underperform and set a new price target of $4.50 from $10.00 previously
Piper Sandler downgraded Sight Sciences from Overweight to Neutral and set a new price target of $5.50 from $15.00 previously
William Blair downgraded Sight Sciences from Outperform to Mkt Perform
Morgan Stanley downgraded Sight Sciences from Overweight to Equal-Weight and set a new price target of $8.40 from $12.00 previously
Citigroup downgraded Sight Sciences from Buy to Neutral and set a new price target of $9.00 from $15.00 previously
Stifel upgraded Sight Sciences from Hold to Buy and set a new price target of $15.00 from $10.00 previously
Needham initiated coverage of Sight Sciences with a rating of Hold
Stifel initiated coverage of Sight Sciences with a rating of Hold and set a new price target of $10.00
William Blair initiated coverage of Sight Sciences with a rating of Outperform
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
Morgan Stanley analyst Cecilia Furlong maintains Sight Sciences (NASDAQ:SGHT) with a Equal-Weight and raises the price target from $5.4 to $6.5.
Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and raises the price target from $6 to $6.5.
Piper Sandler analyst Matt O'Brien reiterates Sight Sciences (NASDAQ:SGHT) with a Neutral and raises the price target from $5 to $6.
Needham analyst David Saxon reiterates Sight Sciences (NASDAQ:SGHT) with a Hold.
Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.30) by 10 percent. This is a 5.71 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $19.265 million which beat the analyst consensus estimate of $18.382 million by 4.80 percent. This is a 2.34 percent increase over sales of $18.824 million the same period last year.
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov
MENLO PARK, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces several Company updates. Preliminary Revenue ResultsThe Company is announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2022. Fourth quarter 2022 total revenue is expected to be in the range of $20.4 million to $20.6 million, an increase of 40% compared to the prior year period and a sequential increase of 10% compared to the third quarter of 2022 at the estimated midpoint.
MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the appointment of Tamara Fountain, M.D. to its Board of Directors, effective July 15, 2022. As part of her duties, Dr. Fountain has joined Sight Sciences' Nominating and Corporate Governance Committee. "Tamara is an accomplished ophthalmologist with both incredible clinical and academic credentials as well as significant ophthalmic leadership experience. She will provide Sight Sciences and our Board of Directors with new and valuable perspectives as we contin
MENLO PARK, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the appointment of Brenda Becker to its Board of Directors, effective March 15, 2022. As part of her duties, Ms. Becker has joined the Nominating and Governance Committee. Ms. Becker has more than 40 years of combined private and public sector experience focused on health policy and legislation. She currently serves as Senior Vice President, Global Government Affairs at Boston Scientific. "Brenda's four decades of public service and private sector expertise i
Holly Sheffield, Medical Technology Executive and Investment Banker Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader James Rogers, Public and Private Medical Technology Investor Imperative Care, Inc. today announced three appointments to the company's Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers. "We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts," said Fred Khosravi, Chairman and CEO of Imperative Care. "Having these high-caliber professionals join our Boar
10-Q - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
SD - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
10-Q - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
DEF 14A - Sight Sciences, Inc. (0001531177) (Filer)
DEFA14A - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
MENLO PARK, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the second quarter ended June 30, 2024, and narrowed financial guidance for full year 2024. Recent Business and Second Quarter 2024 Financial Highlights Generated total revenue of $21.4 million, an increase of 11% compared to the prior quarter and a decrease of 9% compared to the same period in the prior year.Achieved total gross margin of 86%
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 1, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the first quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. Recent Business and Financial Highlights Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.Achieved total gross margin of 86% in the first quarter of 2024 compared to 84% in the same period in the prior year.Reduced ca
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.co
MENLO PARK, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2023, and initiated financial guidance for full year 2024. Recent Financial Highlights Generated full year 2023 total revenue of $81.1 million, an increase of 14% compared to full year 2022 and generated fourth quarter 2023 total revenue of $18.8 million, a decrease of 9% compared to the same period in the
MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, March 7, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webc
MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2023 and withdrew its guidance for full year 2023. Recent Business and Financial Highlights Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.Achieved total gross margin of 86.6% in the third quarter of 2023 compared to 84.3% in the same period in the prior year.Appoint
MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 7, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sight
MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights Generated record second quarter 2023 total revenue of $23.5 million, an increase of 36% compared to the prior year periodAchieved total gross margin of 85.6% in the second quarter of 2023 compared to 84.1% in the prior year period Dry Eye Highlights The SA
MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2023, after the market close on Thursday, August 3, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13D/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G - Sight Sciences, Inc. (0001531177) (Subject)
SC 13D/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13D/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G - Sight Sciences, Inc. (0001531177) (Subject)